[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pots---postural-orthostatic-tachycardia-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pots---postural-orthostatic-tachycardia-syndrome":58},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,106,135,161,186,210],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":70,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":105},"100424417","unhide-project-a-digital-health-platform-to-collect-lifestyle-data-for-brain-inflammation-research-100424417",false,"NCT04806620","Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research","Unhide® Project Also Known as The Unhide® Solve Together Unified Platform","Participants may be either self-diagnosed, or diagnosed by a physician with the following conditions:\n\n* Infection-associated chronic conditions such as Long COVID, chronic Lyme, myalgic encephalomyelitis (ME\u002FCFS), and post-acute neuropsychiatric syndrome (PANS\u002FPANDAS).\n* Neuroimmune, developmental, autonomic, and neurological conditions like migraines, dysautonomia, POTS, multiple sclerosis, and autism spectrum disorder.\n* Autoimmune diseases such as Lupus, Sjogren's Disease, rheumatoid arthritis, myasthenia gravis, ankylosing spondylitis, and related autoimmune conditions.\n\nInflammatory gastrointestinal conditions such as Crohn's Disease, Celiac Disease, and ulcerative colitis.\n\n* Behavioral and mood disorders such as anxiety, depression, bipolar disorder, PTSD, eating disorders, OCD, and other related conditions.\n* \"Healthy\" people (without brain inflammation), including unaffected individuals, unaffected individuals in the same household, and unaffected individuals who are married to relatives and family members.\n* Have consistent internet access and a cell phone, tablet, or PC since this is an online or app-based platform that requires entering data and completing surveys.\n* Currently live in the United States\n* Be able to participate in English (stay tuned for updates about the Spanish language version)\n* Be willing to share symptom and health data through the platform",true,"ALL","2 Years",{"count":20,"type":21},10000,"ESTIMATED","10 Years","OBSERVATIONAL","The unhide® Project is a non-interventional, longitudinal research study designed to establish a secure data repository of demographic, health, and lifestyle information from individuals with brain inflammation and related neuroinflammatory conditions. Participants in the United States aged 2 years and older will provide self-reported health data, biometrics, and symptom diaries through the MyDataHelps™ app (branded as unhide® for this study). The goal is to create comprehensive longitudinal profiles to facilitate research into disease subtypes, causes, diagnostics, and potential treatments, as well as to identify potential participants for future optional studies. \"Healthy\" individuals without brain inflammation are also eligible to participate.\n\nThe digital health research platform used in this study was originally developed and designed by Solve M.E and was called SolveTogether. The Brain Inflammation Collaborative (BIC) expanded upon Solve M.E.'s work to include related diagnoses, pediatric participants, enhance symptom tracking, and more. BIC and Solve M.E. combined Solve Together and unhide®, to create The unhide® Solve Together Unified Platform in 2025.",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69],"Post-Acute COVID-19 Syndrome","ME\u002FCFS","Rheumatic Arthritis","Juvenile Rheumatoid Arthritis (JRA)","Psoriatic Arthritis (PsA)","Ankylosing Spondylitis (AS)","Autoimmune Encephalitis","Celiac Disease","Celiac Disease in Children","Chronic Lyme Disease","Post-treatment Lyme Disease Syndrome","Crohn's Disease","Dysautonomia","Anorexia Nervosa","Bulimia Nervosa","ARFID","Avoidant \u002F Restrictive Food Intake Disorder","Ehlers Danlos Syndrome","Endometriosis","Fibromyalgia (FM)","Long COVID","Lupus","Migraines","Mast Cell Activation Syndrome","Multiple Sclerosis","Myalgic Encephalomyelitis (ME)","Myasthenia Gravis, Generalized","Myasthenia Gravis in Children","Narcolepsy","Obsessive Compulsive Disorder (OCD)","PANDAS","Pediatric Acute-onset Neuropsychiatric Syndrome (PANS)","POTS - Postural Orthostatic Tachycardia Syndrome","General Anxiety Disorder, Social Anxiety Disorder","PTSD - Post Traumatic Stress Disorder","Psoriasis","Traumatic Brain Injury","Tourette's Syndrome","Inflammatory Bowel Disease (IBD)","Autoimmune Diseases","Neurological Diseases or Conditions","Psychiatric Disorder","Sjogren's Syndrome","Ulcerative Colitis and Crohn's Disease",[46,71,72,73,74,75,76,77,78,79,27,80,81,82,83,84,48,85,86,87,88,89,90,91,92],"Myalgic Encephalomyelitis","Chronic Fatigue Syndrome","Longitudinal Natural History Study","Observational","Neuroinflammatory Disease","Brain inflammation","Neuroinflammatory disorders","PANS\u002FPANDAS","Autoimmune encephalitis","Dysautonomia \u002F POTS","Multiple sclerosis","Autoimmune disease","Inflammatory bowel disease (Crohn's, ulcerative colitis)","Celiac disease","Mood disorders (anxiety, depression, bipolar, PTSD, OCD)","Mobile health app","Patient registry","Wearable devices","Fatigue","Post-exertional malaise","Brain Fog","Mental health","RECRUITING","2026-01-20",{"date":96,"type":97},"2026-01-22","ACTUAL",{"date":99,"type":97},"2023-07-05",{"date":101,"type":21},"2030-12-31",{"name":103,"class":104},"Brain Inflammation Collaborative","OTHER",1,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":4,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":113,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":119,"briefSummary":121,"conditions":122,"keywords":123,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":105},"100608157","phase-2-restoring-iron-deficiency-in-pots-100608157","NCT07197905","Restoring Iron Deficiency in POTS","Restoring Iron Deficiency to Expand Blood Volume and Improve POTS","Inclusion Criteria\n\n* Age 18-45 years old.\n* Diagnosis of POTS, defined by a sustained heart rate increase of at least 30 bpm within 10 min of standing or head-up tilt (or absolute upright heart rate \\>120 bpm), in the absence of orthostatic hypotension, and with at least 3 months of symptoms of orthostatic intolerance.\n* Absence of other diseases or medications that can explain orthostatic tachycardia or symptoms.\n* Serum ferritin \\\u003C50 ng\u002Fml.\n* Patients on fludrocortisone will be allowed to participate as long as they have been on the same dose for at least one month before enrollment and continue on the same dose throughout the study.\n\nExclusion Criteria\n\n* Unable or unwilling to provide consent.\n* Pregnancy.\n* Being chair- or bed-ridden.\n* Unable to hold POTS medications during study procedures (i.e., autonomic testing).\n* History of active bleeding (other than menstruation).\n* History of hypersensitivity to any iron preparation of recent (within 6 months) treatment with any IV iron preparation.","FEMALE","18 Years","45 Years",{"count":117,"type":21},12,"INTERVENTIONAL",[120],"PHASE2","People with postural orthostatic tachycardia syndrome (POTS) often have low red blood cell volumes and low ferritin in their blood (a marker of iron storage in the body). The purpose of this pilot study is to investigate whether giving iron to people with POTS who have low ferritin levels will increase the red blood cell volume and improve POTS symptoms.",[58],[124,125],"Postural Tachycardia Syndrome","Iron Deficiency","2025-12-09",{"date":128,"type":97},"2025-12-11",{"date":130,"type":97},"2025-11-24",{"date":132,"type":21},"2026-12",{"name":134,"class":104},"Vanderbilt University Medical Center",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":16,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":118,"phases":143,"briefSummary":145,"conditions":146,"keywords":148,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":105},"100518185","long-covid-immune-profiling-100518185","NCT06027255","Long COVID Immune Profiling","Inclusion Criteria:\n\n* Subjects will be 18 years or older, men and women.\n* History of confirmed COVID-19 infection (positive contact and symptoms, antigen test or PCR).\n* POTS will be defined as the presence of orthostatic tachycardia (\\>30 bpm) and chronic (\\>3 months) pre-syncopal symptoms.\n* Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (\\>30 bpm) and chronic (\\>3 months) pre-syncopal symptoms. Symptoms occurred within 2 months after COVID infection and persistent until enrollment in the study.\n\nExclusion Criteria:\n\n* Individuals with a history of physician diagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack, or who had undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries).\n* Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study.\n* Chronic use of steroids, anti-IL6 (omalizumab), anti-TNF-alpha, other immunosuppressants.\n* Chronic use of NSAID. Should not enroll if taking without one week prior to blood sampling.\n* Treatment with plasmapheresis, IVIG or other immune modulator",{"count":142,"type":21},150,[144],"NA","Parasympathetic nervous system (PNS) is part of the body's autonomic nervous system(PNS) protects body against inflammation. Study shows that reduced PNS function activity is associated with persistent inflammation.\n\nPreliminary data from the studies shows, that post-COVID-19 POTS patients have reduced parasympathetic (PNS) function. Given that the PNS protects against inflammation, this clinical trial aims to prove that post-COVID-19 POTS is caused by reduced PNS activity, which in turn, contributes to persistent inflammation, orthostatic intolerance, and OI symptoms.\n\nThe study will evaluate immune cell activation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity.",[46,58,147],"Autonomic Dysfunction",[149,150,151,46,152],"SARS-CoV-2 infection","POTS","Orthostatic Intolerance","Long hauler COVID infection","2025-12-07",{"date":155,"type":97},"2025-12-15",{"date":157,"type":97},"2024-04-24",{"date":159,"type":21},"2027-07-01",{"name":134,"class":104},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":16,"sex":113,"minAge":168,"maxAge":169,"enrollmentInfo":170,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":177,"lastUpdatePostDateStruct":178,"startDateStruct":180,"completionDateStruct":182,"leadSponsor":184,"locationsCount":105},"100563453","does-a-periaqueductal-gray-vagus-nerve-interface-malfunction-explain-the-nat-hx-with-its-numerous-co-morbidities-100563453","NCT06616363","Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Nat hx With Its Numerous Co-morbidities?","(PAG POTS - NIH) Pediatric Postural Orthostatic Tachycardia Syndrome (POTS) : Does a Periaqueductal Gray-vagus Nerve Interface Malfunction Explain the Natural History With Its Numerous Co-morbidities?","POTS sample\n\nInclusion Criteria:\n\n* symptomatic ≥ 40 bpm rise in heart rate in the first 10 min of a tilt table study without a drop in blood pressure\n* Clinical symptoms of orthostatic intolerance\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Cognitive defects that preclude answering questionnaires or following assessment directions\n* Other chronic diseases\n* Unstable medical conditions\n* Use of narcotics\n* Limited English proficiency\n* Investigator discretion that participant would not be suitable to participate\n* A phone older than 5 years old or unable to support EMA software\n\nPOST INFECTION\n\nInclusion Criteria:\n\n* acute upper respiratory or gastrointestinal infection that required admission to the acute care units but not requiring an ICU stay\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* Chronic prescriptions, history of POTS or orthostatic symptoms, recent inpatient psychiatric admissions, substance use disorder, trauma such as a motor vehicle accident, surgery, or other significant physical or emotional trauma in the last 5 years\n* Cognitive defects that preclude answering questionnaires or following assessment directions\n* Other unstable chronic diseases\n* Unstable medical conditions\n* Use of narcotics\n* Severe depression or anxiety (untreated \u002F unstable)\n* Limited English proficiency\n* Investigator discretion that participant would not be suitable to participate\n* A phone older than 5 years old or unable to support EMA software\n\nHEALTHY CONTROLS\n\nInclusion Criteria:\n\n* Apparently healthy with no known chronic illnesses\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding\n* History of POTS or orthostatic symptoms, migraines, fibromyalgia, chronic fatigue, PTSD. Functional gastrointestinal disorders, fainting, dysmenorrhea, or other chronic pain syndrome, inpatient psychiatric admissions, substance use disorder, trauma such as a motor vehicle accident, surgery, or other significant physical or emotional trauma in the last 5 years\n* Cognitive defects that preclude answering questionnaires or following assessment directions\n* Other chronic unstable diseases\n* Unstable medical conditions\n* Use of narcotics\n* Severe depression or anxiety (untreated \u002F unstable)\n* Limited English proficiency\n* Investigator discretion that participant would not be suitable to participate\n* A phone older than 5 years old or unable to support EMA software","12 Years","21 Years",{"count":171,"type":21},120,"Postural tachycardia syndrome (POTS) is a common and disabling disorder among adolescents. No epidemiologic data exist to support the often cited 0.5 to 2% prevalence. Case series suggest 3 to 5 times greater incidence in girls than boys. POTS is defined in children as daily chronic symptoms of orthostatic intolerance and a 40 bpm rise in heart rate in the first 10 minutes of a tilt study in the absence of orthostatic hypotension. POTS often develops after an acute event like an illness, infection, immunization, head trauma, psychological trauma or surgery. Natural history data are absent for POTS, though some outcome studies exist. Orthostatic symptoms improve in the majority and heart rate changes improve in 38% at 1 year. A 2-year follow up showed small improvement in comorbid symptoms of POTS in a 12 subject cohort followed yearly. In a pediatric 5-year outcome follow up questionnaire study, 86% of adolescents with POTS reported resolved, improved, or intermittent, symptoms, with primarily physical rather than mental health complaints.",[58],[175,176],"PAG activation","Cardiovagal Modulation","2025-09-24",{"date":179,"type":97},"2025-09-26",{"date":181,"type":97},"2024-05-29",{"date":183,"type":21},"2028-07",{"name":185,"class":104},"Virginia Commonwealth University",{"id":187,"slug":188,"hasResults":11,"nctId":189,"briefTitle":190,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":118,"phases":195,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":200,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":4},"100598883","phase-4-effect-of-low-sodium-oxybate-lxb-on-autonomic-symptom-burden-in-idiopathic-hypersomnia-patients-with-postural-tachycardia-syndrome-100598883","NCT07077278","Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome","Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome: a Placebo-controlled, Double-blind, Randomized Withdrawal Study","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. English speaking and capable of signing the informed consent form and comply with the protocol requirements\n3. Diagnosis of IH based on ICSD-3 criteria\n4. Diagnosis of POTS based on the 2011 Consensus Criteria\n5. Oxybate naïve. Participants on daytime alerting medications at baseline can remain on these medications for the duration of the study, provided doses remain stable for the duration of the study. This rule also applies to medications prescribed for the treatment of POTS. All medications known to affect cardiovascular function will be held for the appropriate time periods prior to active stand testing so as not to influence results.\n6. COMPASS 31 ≥ 40 at the screening visit\n7. Agree to use contraceptives consistent with local regulations regarding the methods of contraception for those participating in clinical trials\n\nExclusion Criteria:\n\n1. Hypersomnia due to another medical, behavioral, sleep, or psychiatric disorder\n2. Evidence of untreated or inadequately treated sleep disordered breathing, defined as AHI ≥ 10\n3. History of bipolar or psychotic disorders, major depressive episode, or current suicidal risk\n4. Pregnant or lactating or intends to become pregnant during the study\n5. History of or currently being treated for clinically significant ongoing cardiac arrythmia, heart failure, myocarditis, pulmonary embolism requiring anticoagulation, pulmonary fibrosis or other pulmonary diagnosis that in the investigator's opinion may contribute to symptoms of POTS\n6. Clinically significant uncontrolled active or chronic bacterial, viral, or fungal infection or positive SARS-CoV-2 PCR test at screening\n7. A medical condition that could confound the results of the study or put the participant at undue risk in the investigator's judgment\n8. Intends to have surgery or procedures requiring anesthesia or conscious sedation during the study\n9. Currently participating in another interventional clinical study\n10. Unwilling to remain on a stable regimen of medications during the study\n11. Use of or planned use of intravenous saline infusions during the study",{"count":194,"type":21},25,[196],"PHASE4","The investigators hope to learn if low sodium oxybate (LXB) is an effective treatment for symptoms of idiopathic hypersomnia (IH) and postural tachycardia syndrome (POTS). Previous research has shown that patients with IH also report having symptoms associated with POTS. The researchers have observed that in patients with both IH and POTS, when patients' sleep quality improves, so do their POTS symptoms. The goal of this study is to test this in a controlled way by using LXB as a treatment for both IH and POTS in patients that have been diagnosed with both conditions.",[199,58],"Idiopathic Hypersomnia","NOT_YET_RECRUITING","2025-07-22",{"date":203,"type":97},"2025-07-25",{"date":205,"type":21},"2025-10-01",{"date":207,"type":21},"2027-09",{"name":209,"class":104},"Stanford University",{"id":211,"slug":212,"hasResults":11,"nctId":213,"briefTitle":214,"officialTitle":214,"acronym":150,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":17,"minAge":114,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":118,"phases":218,"briefSummary":219,"conditions":220,"keywords":221,"overallStatus":93,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":105},"100481829","the-effect-of-physical-activity-on-postural-orthostatic-tachycardia-syndrome-100481829","NCT05554107","The Effect of Physical Activity on Postural Orthostatic Tachycardia Syndrome","Inclusion Criteria:\n\n* Patients diagnosed with POTS who have given written informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Patients with myalgic encephalomyelitis are excluded from the study.",{"count":217,"type":21},200,[144],"Postural orthostatic tachycardia syndrome (POTS) is a disorder of unknown origin characterized by orthostatic intolerance and increased heart rate (HR) of ≥ 30 beats\u002Fminute during orthostasis in the absence of orthostatic hypotension. In addition to the orthostatic intolerance and tachycardia, patients with POTS experience several debilitating symptoms including light-headedness, nausea, blurred vision, fatigue, mental confusion (\"brain-fog\"), chest pain and gastrointestinal problems. Several potential underlying mechanisms have been suggested for POTS including autonomic denervation, hypovolemia, hyperadrenergic stimulation and autoantibodies against adrenergic receptors. However, none of these proposed mechanisms has yet led to an effective treatment. Physical activity is recommended as a complimentary treatment in POTS in international guidelines. However, less is known regarding how physical activity could successfully be implemented in clinical practice in patients with POTS. Thus, in the current study, we aim to assess the effect of a 16-week specialized physical activity program in POTS.",[58],[222,150,223,224,225],"Exercise","Training programme","Treatment","Orthostatic intolerance","2025-05-26",{"date":228,"type":97},"2025-05-30",{"date":230,"type":97},"2022-11-02",{"date":232,"type":21},"2028-10",{"name":234,"class":104},"Lund University"]